Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Merck & Company (MRK)
Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 322,025,696
  • Shares Outstanding, K 2,532,644
  • Annual Sales, $ 60,115 M
  • Annual Income, $ 365,000 K
  • 60-Month Beta 0.38
  • Price/Sales 5.40
  • Price/Cash Flow 14.26
  • Price/Book 7.92
Trade MRK with:

Options Overview Details

View History
  • Implied Volatility 17.43% ( +0.68%)
  • Historical Volatility 15.29%
  • IV Percentile 7%
  • IV Rank 15.11%
  • IV High 26.55% on 10/20/23
  • IV Low 15.81% on 02/06/24
  • Put/Call Vol Ratio 0.59
  • Today's Volume 9,125
  • Volume Avg (30-Day) 24,601
  • Put/Call OI Ratio 0.67
  • Today's Open Interest 375,727
  • Open Int (30-Day) 378,067

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 2.13
  • Number of Estimates 7
  • High Estimate 2.24
  • Low Estimate 2.02
  • Prior Year 1.40
  • Growth Rate Est. (year over year) +52.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
120.18 +5.80%
on 01/30/24
130.24 -2.37%
on 02/23/24
+5.87 (+4.84%)
since 01/29/24
3-Month
100.28 +26.79%
on 11/30/23
130.24 -2.37%
on 02/23/24
+26.02 (+25.73%)
since 11/29/23
52-Week
99.14 +28.25%
on 10/19/23
130.24 -2.37%
on 02/23/24
+20.91 (+19.68%)
since 02/28/23

Most Recent Stories

More News
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now

The futures for these two beaten-down stocks could be brighter than their recent pasts.

CRSP : 84.22 (-3.95%)
MRK : 127.15 (-0.81%)
NTLA : 32.12 (-2.07%)
MRNA : 92.24 (-5.38%)
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032

EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NYSE:MRK) EQNX::TICKER_END

TNXP : 0.3782 (+1.07%)
PFE : 26.56 (-1.78%)
LLY : 753.68 (-0.52%)
ABBV : 176.05 (-1.10%)
MRK : 127.15 (-0.81%)
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032

TNXP : 0.3782 (+1.07%)
PFE : 26.56 (-1.78%)
LLY : 753.68 (-0.52%)
ABBV : 176.05 (-1.10%)
MRK : 127.15 (-0.81%)
2 Value Stocks With Monster Yields

These two low-priced large-cap stocks sport ginormous yields.

MRK : 127.15 (-0.81%)
LLY : 753.68 (-0.52%)
NVO : 119.77 (-1.46%)
T : 16.93 (-0.18%)
PFE : 26.56 (-1.78%)
Health Canada Approves KEYTRUDA® in combination with trastuzumab and chemotherapy, as a first-line treatment for patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumours

/CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab),...

MRK : 127.15 (-0.81%)
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month

Investors are still excited about obesity treatments and weight-management drugs.

MRK : 127.15 (-0.81%)
LLY : 753.68 (-0.52%)
NVO : 119.77 (-1.46%)
HARP : 22.94 (-0.04%)
MERCK CANADA ANNOUNCES COLLABORATION WITH VECTOR INSTITUTE TO FURTHER ADVANCE ITS ARTIFICIAL INTELLIGENCE CAPABILITIES AND DRIVE INNOVATION IN HEALTHCARE

/CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, has entered into a multi-year agreement with the Vector Institute in Toronto, an...

MRK : 127.15 (-0.81%)
Will These 3 Pharma Stocks Leave Investors Triumphant in 2024?

The pharmaceutical industry is undergoing a transformative shift driven by the advent of personalized drugs, technological innovations, and growing usage. Against this backdrop, does the inclusion of pharma...

CTMX : 2.45 (-3.54%)
MRK : 127.15 (-0.81%)
NBIX : 130.40 (-3.16%)
Nasdaq Futures Climb on Upbeat Meta and Amazon Results, U.S. Jobs Report Looms

March Nasdaq 100 E-Mini futures (NQH24) are trending up +0.98% this morning as investors cheered forecast-beating quarterly results from tech behemoths Meta and Amazon while awaiting the crucial monthly...

NQH24 : 18,091.00 (+0.05%)
META : 490.13 (+1.26%)
AMZN : 176.76 (+2.08%)
AAPL : 180.75 (-0.37%)
CTVA : 53.52 (-1.87%)
ETSY : 71.69 (+0.97%)
MRK : 127.15 (-0.81%)
HON : 198.73 (+0.59%)
XOM : 104.52 (+0.19%)
CVX : 152.01 (-0.22%)
ABBV : 176.05 (-1.10%)
CHTR : 293.93 (+1.94%)
Why Merck Stock Rocketed Nearly 5% Skyward Today

The company reported healthy sales growth and proffered encouraging guidance to boot.

MRK : 127.15 (-0.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 130.11
2nd Resistance Point 129.48
1st Resistance Point 128.32
Last Price 127.15
1st Support Level 126.52
2nd Support Level 125.90
3rd Support Level 124.73

See More

52-Week High 130.24
Last Price 127.15
Fibonacci 61.8% 118.36
Fibonacci 50% 114.69
Fibonacci 38.2% 111.02
52-Week Low 99.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar